Breaking Finance News

Bioverativ (NASDAQ:BIVV) target price raised to $64.00, issued a report today by Argus

Reporting a possible upside of 0.13%, Argus increased the stock price target of Bioverativ (NASDAQ:BIVV) to $64.00

On 9/15/2017, RBC Capital released a statement on Bioverativ (NASDAQ:BIVV) bumped up the target price from $0.00 to $59.00 that suggested an upside of 0.05%.

Boasting a price of $56.39, Bioverativ (NASDAQ:BIVV) traded 1.17% higher on the day. With the last close up 1.27% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the date range. Bioverativ has recorded a 50-day average of $56.33 and a two hundred day average of $56.33. Volume of trade was down over the average, with 173,337 shares of BIVV changing hands under the typical 993,386

Performance Chart

Bioverativ (NASDAQ:BIVV)

With a total market value of $0, Bioverativ has P/E ratio of 13.56 with a 52 week low of $41.88 and a 52 week high of $57.82 .

About Bioverativ (NASDAQ:BIVV)

Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person's blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.